An initiative known as the Greater Manchester and Pharmaceutical Industry Partnership Group has been launched to improve patients’ access to medicines and use of treatments and provide the first steps to what insiders believe will be a leading drugs research base in the area._x000D_
_x000D_
The partnership, signed between Greater Manchester Health and Social Care Partnership, Greater Manchester Combined Authority, Health Innovation Manchester and the pharmaceutical industry, will explore ways in which the region can pay for medicines based on patient outcomes._x000D_
_x000D_
It will also look at how pharma can help bring about what the ABPI described as “a world-leading site for the research and launch of new medicines” in Greater Manchester. About £1 billion is spent on medicines in Greater Manchester._x000D_
_x000D_
A memorandum of understanding has been signed between bodies within Manchester and the Association of the British Pharmaceutical Industry (ABPI), Ethical Medicines Industry Group (EMIG) and British Generic Manufacturers Association (BGMA)._x000D_
_x000D_
“The group will improve the use and safety of medicines and use the unique data and information capabilities of the NHS to discover, develop, and deliver new medicines and treatments for patients,” the ABPI said._x000D_
_x000D_
ABPI CEO Mike Thompson said: “The (pharmaceutical) industry recognises the challenges faced by the NHS and we are committed to supporting improvements in the use of medicines that can enhance the care and wellbeing of people in the area._x000D_
_x000D_
“We can see from initiatives like the Salford Lung Study how the NHS can embrace innovation to help improve health outcomes. In Greater Manchester we have the infrastructure in place to go even further and create one of the world’s pre-eminent hubs for life sciences research and investment from global companies._x000D_
_x000D_
“By working together with the NHS to improve how to use and learn from real time health data in hospitals and communities we have the best chance of creating the most appropriate and cost-effective medicines for patients in Greater Manchester and throughout the UK.”

LEAVE A REPLY